Medicare Enrolled

Dr. Ann Navar, MD, PHD

Cardiovascular Disease · Dallas, TX
Consulting-driven
6201 HARRY HINES BLVD, Dallas, TX 75390
2146457501
In practice since 2009 (17 years)
NPI: 1609018639 verify on NPPES ↗
High
DATA COVERAGE
Data in 3 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Navar from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Navar? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Navar

Dr. Ann Navar is a cardiovascular disease in Dallas, TX, with 17 years in practice.

Between the years covered by Open Payments, Dr. Navar received a total of $598,925 from 25 pharmaceutical and/or device companies across 316 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in cardiovascular disease. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Navar is High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 17 years in practice$ $598,925 industry payments

Industry Payment Transparency

Open Payments through 2024 ↗
$598,925
Total received (2018-2024)
Avg $85,561/year across 7 years
Top 1% in TX for cardiovascular disease
25
Companies
316
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$580,875 (97.0%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$16,415 (2.7%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$1,635 (0.3%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$152,296
2023
$79,266
2022
$67,542
2021
$46,770
2020
$77,695
2019
$84,858
2018
$90,499

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Eli Lilly and Company
$152,354
Novo Nordisk AS
$82,763
SANOFI-AVENTIS U.S. LLC
$69,780
Amarin Pharma Inc.
$61,024
Novo Nordisk Inc
$48,678
Amgen Inc.
$29,852
Regeneron Pharmaceuticals, Inc.
$20,049
Merck Sharp & Dohme LLC
$19,802
Novartis Pharmaceuticals Corporation
$17,474
AstraZeneca Pharmaceuticals LP
$17,384
Bayer HealthCare Pharmaceuticals Inc.
$15,850
Janssen Scientific Affairs, LLC
$13,156
Bayer Healthcare Pharmaceuticals Inc.
$13,058
PFIZER INC.
$9,750
NOVARTIS PHARMACEUTICALS CORPORATION
$9,162
E.R. Squibb & Sons, L.L.C.
$7,479
Genentech, Inc.
$5,972
Boehringer Ingelheim International GmbH
$1,740
CSL Behring
$1,635
Boehringer Ingelheim Pharmaceuticals, Inc.
$1,600
Janssen Pharmaceuticals, Inc
$132
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)
$100
BOSTON SCIENTIFIC CORPORATION
$98
Esperion Therapeutics, Inc.
$21
AQUESTIVE THERAPEUTICS, INC.
$13
Top 3 companies account for 50.9% of total payments
Associated products mentioned in payments ›
BRILINTA · ELIQUIS · EPANOVA · EVENITY · GENERAL PAIN MANAGEMENT · HYPERLIPIDEMIA - DISEASE · JARDIANCE · Kerendia · LEQVIO · LifeVest · NEXLETOL · NO PRODUCT DISCUSSED · Non-Covered · Ozempic · PRALUENT · PRALUENT ALIROCUMAB INJECTION · Repatha · SYMPAZAN · Vascepa · Victoza · XARELTO
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (97%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers. Total industry engagement is in the top 1% for cardiovascular disease in TX.

Looking for a cardiovascular disease in Dallas?
Compare cardiovascular diseases in the Dallas area by procedure volume, costs, and industry payment transparency.
Browse cardiovascular diseases nearby

Geographic Context

Cardiovascular Diseases within 10 mi
304
Per 100K population
11.7
County median income
$74,149
Nearest hospital
UT OF TEXAS SOUTHWESTERN UNIVERSITY HOSPITAL - WILLIAM P. CLEMENTS JR.
0.0 mi

Data Sources

Provider Registry✓ NPPESWeekly updates
Medicare Enrollment✓ PECOSMonthly updates
Practice Data— No dataN/A
Industry Payments✓ Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 3 of 4 available federal datasets, with a Data Coverage level of High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Navar is a cardiovascular disease, and high industry engagement (consulting-driven, top 1%), with 17 years of practice experience.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Does Dr. Navar receive payments from pharmaceutical companies?
Yes. Dr. Navar received a total of $598,925 from 25 companies across 316 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
What does Data Coverage mean?
Data Coverage (currently High for Dr. Navar) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →

Explore related providers

Same specialty & city
Cardiovascular Diseases in Dallas
Browse cardiovascular diseases in Dallas ranked by procedure volume and transparency data.
Highest volume
Top Cardiovascular Diseases in TX
Cardiovascular Diseases ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Cardiovascular Diseases in TX
Which TX cardiovascular diseases receive the most from drug and device companies.
By company
Eli Lilly and Company Payments to Doctors
See all physicians who received payments from Eli Lilly and Company.
By company
Novo Nordisk AS Payments to Doctors
See all physicians who received payments from Novo Nordisk AS.
By company
SANOFI-AVENTIS U.S. LLC Payments to Doctors
See all physicians who received payments from SANOFI-AVENTIS U.S. LLC.
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →